Endocrine resistance is a major challenge in the management of estrogen-receptor (ER) positive breast cancers. Although multiple mechanisms leading to endocrine resistance have been proposed, the poor outcome of patients developing resistance to endocrine therapy warrants additional studies. Here we show that non-canonical Hedgehog (Hhg) signaling is an alternative growth promoting mechanism that is activated in tamoxifenresistant tumors. Importantly, PI3K/AKT pathway plays a key role in regulating Hhg signaling by protecting key components of this pathway from proteasomal degradation.
Introduction
Breast cancer is the most common cause of cancer related death in women globally.
Death rates from breast cancer have been steadily decreasing since 1990, which is attributed largely to better screening methods and improved treatment options. Perhaps, the major breakthrough in the treatment of breast cancer was the development of targeted therapies with drugs such as tamoxifen, a selective estrogen receptor (ER) modulator that blocks estrogen signaling. This therapeutic approach has been successfully used to treat approximately two-thirds of ER positive breast cancers resulting in 50% improvement in disease-free survival (1) . A recurring problem is, however, the development of acquired resistance to ER-targeted therapies in about 30-40% of the woman treated with tamoxifen for 5 years. Several signaling pathways are implicated in tamoxifen resistance including PI3K/mTOR/Akt, HER2/ERB and IGF-R pathways (2) (3) (4) (5) (6) . A few agents targeting these pathways in hormone-refractory breast cancers are in clinical trials (5, 7) . To date however, there is no approved targeted therapy to improve outcomes in hormonerefractory breast cancers without resorting to chemotherapy.
The hedgehog (Hhg) signaling pathway is highly conserved and plays a crucial role in vertebrate embryogenesis (8) . The Hhg ligands (SHH, IHH and DHH) bind to the cell surface receptor Patched (PTCH), which otherwise inhibits the activity of the transmembrane receptor like protein Smoothened (SMO). Release of SMO from PTCHmediated repression results in post-translational processing of the GLI (glioma associated oncogene homolog) -zinc-finger transcription factors. Three mammalian GLI proteins are known to exist out of which GLI1 and GLI2 usually act as transcriptional activators and GLI3 acts as a transcriptional repressor (9) . Aberrant activation of the Hhg pathway 4 has been reported in several cancers including basal cell carcinomas, medulloblastomas, pancreatic adenocarcinomas and glioblastomas (10) (11) (12) . Several lines of evidence point toward involvement of Hhg signaling in breast carcinogenesis, and hence provide an attractive, rational therapeutic target in treating this cancer (13) .
Mice with heterozygous disruption of Ptch1 demonstrated marked abnormalities in mammary glands resembling ductal dysplasias and hyperplasias (14) . Further, expression of activated human SMO (SmoM2) in mouse mammary epithelium led to increased proliferation, altered differentiation, and ductal dysplasias distinct from those caused by Ptch1 heterozygosity (15) . Hhg signaling is also activated in human mammary stem/progenitor cells and is downregulated upon cell differentiation (16) . It may also play a part in breast cancer progression through its role in communication between epithelial and stromal compartments (17, 18) . Furthermore, higher expression of SHH in breast tumors was significantly associated with increased risk of metastasis and breast cancerspecific death (19) .
Here we present in vitro and in vivo data demonstrating the dependency of endocrine resistant breast cancer cells on activated Hhg signaling for growth and the mechanism for this activation. In addition, we also present data supporting the clinical use of Hhg inhibitors in endocrine resistant tumors. (20) . MISSION siRNA universal negative Control and siRNA to SMO and GLI1 were from Sigma.
Materials and Methods

Reagents
Cell Culture and tissue procurement: Tamoxifen sensitive MCF7 cells and OHTR100 cells (resistant to 100nM tamoxifen) were obtained from Dr. Kenneth P. Nephew (Indiana University, Indiana) and maintained as described (21) . OHTR100 cells were further cultured in 500nM 4-hydroxy tamoxifen (4-OHT) for one month to obtain the OHTR500 cells, followed by exposure to 1000nM tamoxifen to obtain the OHTR1000 cells. T47D cells were obtained from ATCC (American Type Culture Collection, Virginia, USA) and maintained as instructed. Cell lines were not passaged longer than six months after receipt. Primary human breast samples were obtained from the Stephanie Spielman Tissue Bank (protocol 2003C0036).
RT-PCR Analysis: cDNA was synthesized from DNase-treated total RNA and gene expression (SHH, SMO, GLI1, GLI2, GLI3) was measured in quadruplicate using Taqman assays (Applied Biosystems). Expression of SNAIL, MYC and BMI1 was measured using Sybr Green chemistry.
Western blot analysis:
Whole cell extracts were prepared in the cell lysis buffer, followed by immunoblotting as described (22) . Protein expression was quantified by ImageJ software (http://rsbweb.nih.gov/ij/).
Plasmids, transfections and luciferase assay: 8×3 Gli BS-į5 -Luc plasmid is a gift from Dr. Hiroshi Sasaki (9) . pLKO.1-shGLI1 plasmid was from Thermo Scientific. Cells (1.6×10 5 /well) seeded in 24-well plate and transfected for 6h with 8×3'Gli-BS-į5'-Luc 6 plasmid and pRLTK (internal control, Promega) using Lipofectamine™ 2000 (Invitrogen). Luciferase activity was measured using Dual-Luciferase Assay System (Promega) after 48h of transfection. OHTR2 nd cells were routinely used to study the mechanism of Hhg pathway activation as this pathway is highly active in these cells.
Cell proliferation assay: Cells (4000/well) seeded in 96-well plates were serum starved overnight and treated with 5μM tamoxifen for 72h. Cell proliferation was monitored using MTT assay kit (Roche Molecular Biochemicals), following company's protocol.
Colony formation assay:
The assay was conducted as described previously (23) . Briefly, exponential growth cells (500/well) in 6-well plates were treated with indicated concentrations of tamoxifen for two weeks. When colonies were readily visible (>50 cells/colony) they were fixed in methanol and stained with 1% crystal violet solution. The colony number was quantified using AlphaView Software 3.1 (FluorChem Q). of America) subcutaneously. Freshly formulated suspension of GDC-0449, in 0.5%methylcellulaose, 0.1% Tween-80 (24) was administered orally at 100mg/Kg body weight (25) , twice daily for 10 days. Length (L) and width (W) of the tumors were measured twice a week, and tumor volume was calculated using the formula LW 2 /6, as previously described (26) . At least five animals per group were used in each experiment.
Immunohistochemical (IHC) analysis:
The expression of Hhg markers in primary tumors was determined by IHC using Benchmark LT automated system (Ventana Medical Systems, Tucson, AZ) (27) . The positive and negative controls are expressing and non-expressing tissues respectively, with and without primary antibody. Expressions of the markers were scored based on percentage positive cells and intensity of the staining by two independent pathologists. In case of discrepancy an independent reader was consulted and consensus was obtained. A score 10% was considered positive. All clinical follow up was derived from the James Tumor Registry, OSU with a median follow -up of 96 months (0.93, 139.1months).
Statistical Analysis:
The standard two-tailed Student's t-test was used for two data sets. 
Results
Hedgehog signaling pathway is aberrantly activated in tamoxifen resistant cell lines
As a first step to determine if Hhg signaling pathway is activated in tamoxifen resistant breast cancer cells, the expression of genes encoding Hhg pathway components and their protein levels were analyzed in tamoxifen sensitive and resistant breast cancer tamoxifen (OHTR100, OHTR500 and OHTR1000) (Fig.S1A ). About 20% decrease in cell growth was observed when the resistant cells were exposed to 2.5 and 5PM tamoxifen ( Fig. S1B) , demonstrating the resistance. Real-time RT-PCR revealed a consistent increase in expression of SHH, SMO, and GLI1 in the OHTR cell panel that correlated with the level of tamoxifen resistance (Fig 1A) , while GLI2 and GLI3 expression were not significantly changed (data not shown). There was no marked change in the amount of PTCH RNA in OHTR cells (Fig. 1A) . Western analysis of the Hhg signaling molecules confirmed a marked increase in the protein levels of SMO and GLI1 in the resistant cells whereas SHH was not detected (Fig. 1B) . The protein levels of PTCH ( Fig. 1B ), GLI2 and GLI3 remain unaltered (Fig. S1C ).
It is known that T47D cells are relatively more resistant to tamoxifen, compared to other ER positive cell lines (28) . Consistent with this finding, the level of SMO and GLI1 proteins were significantly higher in the T47D cells compared to tamoxifensensitive cell lines MCF7 and BT474 (Fig.1C) . In contrast, the expression of PTCH was comparable in all cell lines. Because GLI1 is a transcription factor we tested the functional significance of increased expression of this gene in the tamoxifen sensitive and resistant cells, using a GLI responsive luciferase reporter vector (9) . Analysis of luciferase expression revealed a
We next analyzed the expression of the Hhg target genes in the MCF-7 and OHTR cell lines. The expression of SNAIL, BMI1, and MYC mRNA in tamoxifen resistant cells were significantly increased (2.5 to 4-fold) (Fig. 1F ). MYC and BMI1 protein levels were also found to be markedly higher (~5-fold and >17-fold respectively) in the tamoxifen resistant cells, and directly correlated with higher levels of tamoxifen resistance (Fig. 1G) .
Tamoxifen resistant xenografts in mouse mammary gland undergo micro-metastasis with concurrent increase in Hedgehog signaling
To study further the relationship between activated Hhg signaling and tamoxifen resistance of breast tumors in vivo, tumor xenografts were established in Balb/c nude mice using OHTR100 cells. The tumors were serially passaged in mice treated with tamoxifen and a consistent increase in the growth rate of the tumors was observed after each passage ( Fig. 2A) . Microscopic analysis of H&E sections from the liver and lung of mice after the third passage revealed metastatic lesions in both tissues, indicating that the cells acquired a more aggressive phenotype after in vivo passage (Fig. 2B) 2D ) and increased mammosphere formation (Fig.S2A , B) in in vivo passaged cells. The expression of SMO and GLI1 increased after successive passages and were significantly higher (~3-fold) in the cells derived after the second and third passage in the mice (Fig. 2E) . Similar increases in expression of the GLI1 target genes Myc was also observed (Fig.2E) . Immunocytochemical analysis revealed a marked increase in SMO, GLI1 and BMI1 in tamoxifen resistant cells, with distinct nuclear localization of GLI1 (Fig. 2F) . These data demonstrated a strong relationship between acquisition of the aggressive phenotype of tamoxifen resistant cells in vivo and the activation of Hhg signaling in the resistant tumors.
Knockdown of Hhg pathway components inhibits growth of tamoxifen resistant cells
To determine the functional significance of Hhg pathway in tamoxifen resistance, we depleted SMO and GLI1 from OHTR2 nd cells using the respective siRNA pools (Fig.   3A) . A 60% decrease in SMO and 30% decrease in GLI1 protein level were routinely observed in the siRNA transfected cells (Fig 3A) . Comparison of cell proliferation to the scrambled siRNA transfected control cells revealed a 66% (p <0.001) and 25% (p<0.001) decrease in growth of SMO and GLI1 depleted cells, respectively. In the presence of 1.0PM tamoxifen, the growth of SMO depleted cells was further reduced by 25% (p<0.001) and that of GLI1 depleted cells by an additional 12% (p<0.05), whereas the growth of the control cells remained unaffected (Fig. 3B) . When assessed for clonogenic growth, we observed a 30% (p<0.001) decrease in colony formation upon depletion of both SMO and GLI1. In the presence of 1.0 and 2.0PM tamoxifen, the colony formation was reduced by ~50% (p<0.001) and 85% (p<0.01) respectively when SMO or GLI1 was depleted compared to the tamoxifen treated control cells (Fig. 3C) . Cell cycle analysis revealed significant retention of GLI1 depleted cells in the G1 phase both in absence 
(p<0.001) and presence of tamoxifen (p<0.001) at 6 and 12 hours compared to the control cells (Fig. 3D) . There was no increase in the sub-G0 population or apoptosis ( Supplementary Fig. S3A and B) . Similar growth suppression and sensitization to tamoxifen were also observed in two independently derived GLI1 shRNA knockdown T47D clones (supplemental Fig. S3C-E) . These clones showed decreased growth in the presence of tamoxifen and, decreased colony formation.
Analysis of target gene expression in SMO depleted OHTR2 nd cells and GLI1
depleted T47D cells revealed a marked reduction in the MYC protein (45%, Fig. 3E ) and RNA level in both the cell lines (OHTR: 60%, T47D: 63-75%, Fig. 3E and Supplementary Fig. S3F ). Further, the expression of BMI1 and SNAIL were also significantly reduced in these cells (~50% and >75% respectively, Fig. 3E , Supplementary Fig. S3F ) and GLI1 depleted OHTR cells (data not shown).
The PI3K/AKT pathway activates Hhg signaling in tamoxifen resistant breast cancer
To elucidate the mechanism underlying aberrant activation of Hhg pathway in tamoxifen resistant breast cancer, we first used the GLI-Luciferase reporter to determine whether a SHH autocrine loop could account for pathway activation in resistant cell.
While the GLI reporter was strongly activated in OHTR 2nd cells, addition of recombinant SHH ligand had no effect on luciferase activity in OHTR 2nd or MCF-7 cells (Fig. 4A ).
The data suggested that a non-canonical pathway might function to activate Hhg signaling components and contribute to tamoxifen resistance of these cells. 
nd cells were routinely used to study the mechanism of Hhg pathway activation as this pathway is highly active in these cells.
We hypothesized that the PI3K/AKT pathway, known to be associated with poor patient outcome in endocrine resistant breast tumors (29) , (30) is involved in Hhg pathway activation. Consistent with this hypothesis, treatment with 20PM LY294002, a specific inhibitor of PI3K, resulted in a 50% decrease in GLI-dependent luciferase activity in OHTR2 nd cells, but not in MCF7 cells (Fig. 4B) . Similar inhibition of the GLIreporter was also observed when cells were treated with 500nM of Wortmanin (45%, p<0.05) or 20PM of a specific AKT inhibitor [1L-6-hydroxymethyl-chiro-inositol-2-(R)- Fig.S4A ). The inhibition by LY294002 was rescued when the constitutively active PI3K subunit P110 or an activated form of AKT was ectopically expressed in these cells (Fig. 4C & D) .
2-O-methyl-3-O -octadecylcarbonate] (46%, p<0.05) (Supplementary
Furthermore, when vectors expressing dominant negative versions of P110 or AKT were transfected in the OHTR 2nd cells, the luciferase activity decreased by >90% and 25%, respectively ( Fig 4E) . Conversely, co-expression of a constitutively active form of P110 in MCF7 cells resulted in nearly 2-fold (p<0.01) increase in GLI-reporter activity ( Fig   4F) . A small but significant increase in reporter activity was also observed in MCF-7 cells forced to express constitutively active AKT (0.25-fold, p=0.045) (Fig 4F) .
To explore a potential mechanism underlying the PI3K pathway-activated Hhg signaling, SMO and GLI1 protein levels were measured in LY294002 treated OHTR2 nd cells. These cells showed ~50% decrease in SMO protein levels compared with vehicle (DMSO) treated controls (Fig. 4G, left panel) . A similar reduction in GLI1 level was also observed after treatment with LY294002 (Fig. 4G, right panel) . GSK3E is a serine-threonine kinase that is negatively regulated by PI3K/AKT mediated phosphorylation. We hypothesized that GSK3E -mediated phosphorylation of SMO and GLI1 facilitate ubiquitination and subsequent proteasomal degradation of these proteins in breast tumor cells. Activation of AKT in tamoxifen resistant cells could thus rescue proteasomal degradation of these proteins by inhibiting GSK3E Indeed, bioinformatics analysis using GPS software (31) revealed the presence of several potential phosphorylation motifs in SMO (Supplementary Table S1 ) and in GLI1 (Supplementary Table S2 (Fig. 4H) . Furthermore, stabilization of SMO and GLI1 by LiCl and MG132 was blocked when the cells were treated simultaneously with the PI3K inhibitor (Fig. 4I, Supplementary Fig. S4B ).
These data demonstrate that GSK3E -mediated phosphorylation can indeed lead to proteasomal degradation of these two proteins and that the PI3K/AKT pathway plays a key role in stabilizing these signaling molecules thereby promoting activation of this pathway in the resistant cells.
GDC-0449, a small molecule inhibitor of SMO inhibits tamoxifen resistant cell growth both in vitro and in vivo.
GDC cancer. We used this compound to determine if the growth of tamoxifen resistant cells could be suppressed with this inhibitor alone or in combination with tamoxifen using both in vivo and in vitro assays (Fig 5A-D) . For in vivo assays, xenografts were established in athymic nude mice with OHTR2nd cells. After implanted tumors reached ~100mm 3 in size, the mice were randomized in four groups: vehicle, tamoxifen alone, GDC-0449 alone and both tamoxifen and GDC-0449. The mice were treated for 10 consecutive days and the tumor growth was monitored for an additional two weeks (Fig.   5A ). While the control group tumor reached 500mm 3 in volume at the endpoint of the assay, the GDC-0449 treated tumors failed to grow. In fact, the tumors shrank by ~50%
from the day of treatment by day 24. Treatment with tamoxifen alone caused a 2.5 fold reduction in tumor size compared to the control group while the combination of both tamoxifen and GDC-0449 had no additional effect compared to GDC-0449 alone ( (Fig. 6B) . When analyzing this data based on molecular subtypes, among ER positive tumors (N=230), epithelial GLI1 expression correlated with worse DFS in patients with node-positive disease only (p<0.01) (Fig.6C) .
For overall survival, univariate survival analysis results were presented in Table 1C .
Multivariate analysis selected the final model in which grade and ER were stratified and still demonstrated a significant GLI effect [p=0.014, HR 2.156 (1.17, 3.98)] after adjusting for nodal status (Fig.6D) .
Furthermore, we asked the question whether among patients that received tamoxifen as part of their adjuvant therapy, if high GLI1 expression resulted in worse DFS. Among the 98 ER positive patients who received tamoxifen as part of their adjuvant therapy, there were only a total of 20 events in 10 years of follow up and no statistically significant difference was seen between the groups with high or low expression of GLI1. Considering the overall excellent prognosis in this subset of patients, a larger sample size is needed to identify a statistically significant difference in clinical outcomes.
Discussion
We demonstrate here for the first time the efficacy of targeting Hhg pathway using a small molecule SMO inhibitor in improving outcomes in tamoxifen-resistant tumors.
Acquired resistance to endocrine therapy such as tamoxifen is a major clinical concern in the management of hormone-receptor positive breast cancer patients which is clearly a complex phenomenon involving multiple pathways (32) (33) (34) (35) (36) . Receptor tyrosine-kinases One of the major challenges in treating a drug-resistant tumor is the complex networking pathways that are involved in the cross-talk between the distinct signaling pathways. The PI3K/AKT pathway is one of many pathways that contribute to endocrine resistance (37) . Activation of the PI3K/AKT and the p42/44 mitogen-activated protein kinase pathways by receptors such as EGFR, IGF1-R, suppresses the expression of ER and PR (29, (38) (39) (40) (41) (42) and therefore, reduce estrogen dependence. Our work clearly demonstrates cross talk between PI3K/AKT and Hhg pathway, and provides an additional mechanism for PI3K/AKT mediated endocrine resistance. Importantly, we demonstrated that increased activity of PI3K/AKT activity could stabilize SMO and GLI1 protein by suppressing GSK3E -mediated phosphorylation and proteasomal degradation, leading to non-canonical Hhg pathway activation. Although a previous study reported cross-talk between PI3K/AKT and Hhg pathway, it is in NIH3T3 cells through activation of Hhg ligands (43) . Our data suggests a rationale for combined targeting of PI3K/AKT and Hhg pathway to effectively overcome endocrine resistance. 
